Prognostic value of elective neck dissection in adenoid cystic carcinoma of head and neck: a metaanalysis

Suton, Petar; Lukšić, Ivica

Source / Izvornik: International Journal of Oral and Maxillofacial Surgery, 2021, 50, 1403 - 1407

Journal article, Accepted version Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)

https://doi.org/10.1016/j.ijom.2021.01.010

Permanent link / Trajna poveznica: https://urn.nsk.hr/urn:nbn:hr:105:091777

Rights / Prava: In copyright/Zaštićeno autorskim pravom.

Download date / Datum preuzimanja: 2025-03-13



Repository / Repozitorij:

Dr Med - University of Zagreb School of Medicine Digital Repository





1	Prognostic value of elective neck dissection in adenoid cystic carcinoma of
2	head and neck: A meta-analysis. A call for randomised trial and
3	international consensus
4	
5	Petar Suton ¹ , Ivica Luksic ²
6	
7	
8	¹ Department of Radiotherapy and Medical Oncology, University Hospital for Tumours,
9	University Hospital Center "Sisters of Mercy", Ilica 197, 10000 Zagreb, Croatia
10	² University of Zagreb School of Medicine, Department of Maxillofacial Surgery, University
11	Hospital Dubrava, Ave. Gojko Susak 6, 10000 Zagreb, Croatia
12	
13	
14	University of Zagreb School of Medicine, Department of Maxillofacial Surgery, University
15	Hospital Dubrava, Ave. Gojko Susak 6, 10000 Zagreb, Croatia
16	
17	
18	
19	Corresponding author:
20	Prof. Ivica Luksic, MD, MSc, PhD
21	Department of Maxillofacial Surgery, University Hospital Dubrava
22	Ave. Gojko Susak 6, 10000 Zagreb, Croatia
23	Phone: +385 1 2903 431; Fax: +385 1 2864 250
24	E-mail: luksic@kbd.hr
25	Running heads: Elective neck dissection in adenoid cystic carcinoma of head and neck

26 ABSTRACT

27 Adenoid cystic carcinoma of head and neck (AdCCHN) is uncommon salivary gland cancer characterised for infrequent neck metastases, high rate of local and distant recurrence. The 28 aim of this meta-analysis was to analyse significance of elective neck dissection (END) in 29 terms of overall survival (OS) in patients with AdCCHN. A systematic literature search and 30 meta-analysis was performed. Endpoint assessed by this meta-analysis included 5-year OS 31 32 (death from any cause). Statistical heterogeneity was assessed using the Cochrane Q test and I^2 statistic. A pooled odds ratio (OR) was reported with 95% confidence interval (CI). There 33 were 1934 patients in END arm and 3083 in the observation group. The pooled OR, 34 35 calculated for END vs. observation, was 0.94. Patients receiving END had similar risk for death compared to observation cohort (P=0.76). No significant difference in final outcome 36 after patient's stratification based on T stage was identified (OR for T1/T2 1.27, P=0.39; OR 37 38 for T3/T4 0.95, P=0.90). Observation for cN0 neck is a reasonable option in AdCCHN. This findings suggest conduction of prospective trials on indications and extent of END in 39 40 AdCCHN.

41

42 Keywords: head and neck cancer; carcinoma, adenoid cystic; neck dissection; neck
43 metastases; survival

44

46 INTRODUCTION

Adenoid cystic carcinoma of head and neck (AdCCHN) is a rare, slow growing, malignant
epithelial tumor, comprising about 1% of all head and neck malignancies and about 10-15%
of all salivary gland neoplasms.¹ This tumor is known for its slow progression accompanied
with perineural invasion (PNI), rare lymphatic spread to the neck, high rate of local
recurrence and delayed occurence of distant metastases.
Whereas therapeutic neck dissection (TND) is performed in all clinically node-positive (cN+)

patients, management of cN0 neck is still controversial and elective neck dissection (END) is 53 not routinely carried out in patients with AdCCHN. While isolated lymph node involvement 54 55 may not have significant effect on survival, it is a risk factor for subsequent development of distant metastases.² Recently, we reported largest systematic review on END in AdCCHN 56 analysing important features of cN0 treated neck (incidence of occult neck metastases, lowest 57 58 involved region, extranodal extension (ENE), the role of sublocalization with respect to regional metastases etc.).³ The aim of this meta-analysis was to further address these 59 important issues and to determine impact of prophylactic neck management in patients with 60 AdCCHN with respect to survival. Additional effort was done in order to determine 61 prognostic value of END based on the T stage of the primaries (early vs advanced disease). 62 To our knowledge this is first meta-analysis of the role of END in AdCCHN. 63

64

65 MATERIALS AND METHODS

Inclusion criteria were: (1) diagnosis of AdCCHN, (2) studies with patients undergoing 66 primary surgical treatment including END group and those being observed for the cN0 neck, 67 (3) information on OS rates among examined arms (END vs observation). Based on our 68 previous article on END in AdCCHN,³ preliminary analysis identified 1490 AdCCHN studies 69 with five reports which met criteria mentioned above. Study by Lee et al.⁴ was excluded due 70 to fact that survival analysis was done comparing overall N+ rates vs N0 AdCCHN. 71 Difference in OS between END vs no END group was not found (p=0.178), however there 72 were no survival curves or absolute numbers on which analysis could be done. Also, 73 74 additional search was done covering period between the date of last search (August 5, 2019) 75 and July 25, 2020. One of the additionally identified studies (N=106) met these criteria. Therefore, five studies with 5017 patients were included in the final meta-analysis (Table 76

77 1).⁵⁻⁹

78

79 *Statistical analysis*

Endpoint assessed by this meta-analysis included 5-year OS (death from any cause) Statistical 80 heterogeneity was assessed using the Cochrane Q test and I² statistic. Statistically significant 81 heterogeneity was considered present at P<0.10 and I^2 >50%. When homogeneity was 82 minimal (P>0.10, $I^2 < 50\%$), a fixed-effects model was applied for meta-analysis of disease 83 outcome (OS); otherwise, a random effects model was used. Egger's test was used to estimate 84 85 potential publication bias. A pooled odds ratio (OR) was reported with 95% confidence interval (CI). Analyses were conducted using statistical software Stats Direct version 3.0.165 86 (Stats Direct Ltd., Altrincham, United Kingdom). 87

88

90 **RESULTS**

91 This meta-analysis included four studies with a total of 5017 AdCCHN patients undergoing

92 END in 1934 cases, while 3083 patients have been observed for cN0 neck. Included studies

are presented in **Table 1**. There were 315 deaths from any cause in END group at 5-year

follow-up, while 564 deaths were reported in the observation cohort at the same time period.

95 **Table 2** shows patient's demographic and clinical characteristics.

96

97 5-year OS (all stages AdCCHN)

98 The analysis of pooled studies showed significant heterogeneity ($I^2=74.3\%$, Cochran

99 Q=15.59, P=0.004) without publication bias (Egger: bias= 0.21, P=0.93) (Figure 1).

100 Therefore, the random effect model was used. The data from five studies were available for

101 the analysis of 5-year OS (Figure 2). There were 1934 patients in the END group and 3083

102 patients in the observation group. The pooled OR, calculated for END vs. observation, was

103 0.94 (95% CI, 0. 63- 1.40; P=0.76).

104

105 5-year OS (early vs advance stage AdCCHN)

106 Early AdCCHN

107 The analysis of pooled studies showed significant heterogeneity ($I^2=61.1\%$, Cochran Q=2.57,

108 P=0.11). Therefore, the random effect model was used. Due to small number of patients bias

109 indicator could not be calculated. The data from two studies were available for the analysis of

110 5-year OS (Figure 3). There were 579 patients in the END group and 1469 patients in the

observation group. The pooled OR, calculated for END vs. no END, was 1.27 (95% CI 0.74 -

112 2.16; P=0.39).

113

115 Advanced AdCCHN

- 116 The analysis of pooled studies showed significant heterogeneity ($I^2=79.6\%$, Cochran Q=4.89,
- 117 P=0.03). Therefore, the random effect model was used. Due to small number of patients bias
- 118 indicator could not be calculated. The data from two studies were available for the analysis of
- 119 5-year OS (Figure 4). There were 345 patients in the END group and 903 patients in the
- 120 observation group. The pooled OR, calculated for END vs. no END, was 0.95 (95% CI 0.43 -
- 121 2.09; P=0.90).
- 122
- 123
- 124
- 125

126 **DISCUSSION**

127 AdCCHN accounts for 3-5% of all head and neck malignancies. It's characterized by

128 intermediate grow rate, low probability of regional lymphatic involvement and frequent

129 distant metastases/local recurrences.

Whereas TND is performed in all cN+ patients, management of cN0 neck is still contoversial 130 and END is not routinely carried out in patients with AdCCHN. The decision regarding END 131 132 performance should be based on both the incidence of occult lymph node metastases as well as expected impact of applied treatment on survival. Given the lack of data on incidence of 133 neck metastases and it's influence on final outcome, the association between occult neck 134 135 disease and OS remain inconclusive. The main objective of this study was to determine impact of END on survival in order to guide indications for prophylactic neck treatment in 136 AdCCHN patient's. 137

Previously, we have published an article on important features among AdCCHN patients 138 undergoing END.³ In the largest systematic review on the examined topic, we analysed 18 139 140 studies with a total of 5767 AdCCHN undergoing END in 2450 cases. According to our results elective lymphadenectomy was employed in 42.5% of patients with AdCCHN (range 141 9.2 - 100 %) and the overall rate of occult neck metastases was reported to range between 0% 142 143 and 43.7%, the average being 13.9%. However, no meta-anaylsis on END and survival was performed due to high heterogeneity among examined studies. Also, there are no published 144 meta-analysis on this topic: one meta-analysis combined both TNDs and ENDs as one clinical 145 setting which makes these results and recommendations questionable,¹⁰ while other analysed 146 other features of this tumor (molecular mutations, chromosomal abberations, lympovascular 147 and perineural invasion). Additionally, no randomised trial on this topic has been conducted 148 to date. 149

Given the fact that OS is the single most important feature of any relevant trial in oncology 150 when examining potential efficacy of therapy, we decide to explore this end-point in cohort of 151 AdCCHN undergoing END. In this meta-analysis, control group was consisted of AdCCHN 152 patients with identical disease stage (cN0) being observed for the neck. 153 According to the results of this meta-analysis, observation of the cN0 neck is a rationale 154 option for AdCCHN patients with cN0 irresepective of T stage. It's seems that END is not 155 associated with survival benefit in any subgroup of patients having this rare tumour. 156 Rational explanation for this findings could be found in biological behaviour of AdCCHN. 157 While neck metastases in vast majority of head and neck carcinomas are the single most 158 159 important prognosticator of poorer outcome, this survival disadvantage may be less prominent is AdCCHN due to indolent course of this tumour. Additonal explanation could be potential 160 higher rates of elective neck irradiation in observation cohort resulting in similar neck control 161 162 compared to those achieved by neck surgery. However, most historical data analysing postoperative irradiation showed that this modality reduces local recurrence rates without 163 influencing final outocome.^{5,11} Furthermore, in this study patients within END group 164 underwent adjuvant radiotherapy more often (absolute difference 5.7%) compared to no END 165 cohort. On the contrary, insufficient data on adjuvant radiotherapy features (included regions, 166 167 dose distribution, whether field covered the neck electively in observation cohort, included field in END group with/without occult neck metastases) make it impossible to draw clear 168 conclusions on its role in cN0 setting. Also, in this meta-analysis observation group had less 169 favorable tumor/treatment releated characteristics (almost half of the cases were minor 170 salivary gland AdCC and radiotherapy was less used), while other variables were comparable 171 (age, gender and T1/T2 stage disease) which probably exclude possibility of selection more 172 favorable patients in the group in which END was omitted. 173

The main weakness of the analysis is the non-randomised design of included studies. Due to the lack of randomisation, the groups could vary in terms of characteristics associated with outcomes. While our results (i.e. **Table 2**) show differences between groups for major salivary glands there could also be differences for other variables not reported by this study. As with any analysis of studies of this design, the size of differences between groups could be confounded by other variables.

Additionally, publication, availability, and selection biases are a potential concern for metaanalyses, but many reviewers neglect to examine or discuss them.¹² Reviewers should seek individual participant data from all studies identified by a systematic review; include, where possible, aggregate data from any studies lacking individual participant data to consider their potential impact; and investigate funnel plot asymmetry.¹²

Also, these results must be taken with caution due to high hetrogeneity of the data. Another weakness of this studywas no stratification among END and no END subgroup based to the T stage (only two studies had this information) or hystological subtype of the AdCCHN with respect to survival which could influence obtained results.

Also, AdCCHN is not a homogenous entity and it does behave differently in its propensity to metastasize to the neck from different sites. Although, survival was not associated with any subgroup of patients we were not able to subdivide patients by site due to insufficient data from individual studies. It's well known that there are subsites with higher risk of occult neck

193 metastases which could potentially benefit from END (i.e. floor of mouth and tongue

194 primaries with higher T stage). Whether in this subpopulation END actually affects survival

195 may never be able to be proven given the small numbers from published series.

196 According to this meta-analysis, although END is reported to provide staging information and

is associated with a prolonged regional control, it does not affect survival. Despite the fact

198 that neck status is the most important prognosticator in vast majority of the head and neck

199	malignancies, commonest pattern of recurrence and death among AdCCHN patients are
200	distant metastases and/or local recurrence. To date, only one study demonstrated survival
201	benefit of END being observed in a cohort of patients with advanced stage major salivary
202	gland (MSG) AdCC, with the effect being most pronounced in those undergoing adjuvant
203	radiotherapy (8% difference in survival between END vs observation group and absolute
204	improvement in survival of 11.5% at 5-year in those receiving adjuvant irradiation compared
205	to END alone). ⁸ However, subgroup analysis showed that observation cohort had higher
206	percentage of minor salivary gland primaries (56.5% vs. 24.8%) which is sublocalization
207	associated with poorer survival compared to the similar stage MSG AdCC.
208	In conclusion, it seems that initially cN0 neck should be rather observed for neck recurrence
209	than treated "upfront" with prophylatic surgery of the neck. Most of the observed patients do
210	not develop regional metastases during follow-up period making END questionable in terms
211	of prognosis. This meta-analysis suggest conduction of prospective trial with balanced
212	experimental and control arm in terms of other prognostic factors (age, gender,
213	sublocalization of the primary, T stage, adjuvant radio(chemo)therapy, histological subtype
214	of the AdCCHN etc.) and international consensus on the neck treatment in cN0 setting in
215	order to assess it's role and treatment planning in AdCCHN patients.
216	
217	Declarations
218	Funding: No funding

Competing Interests: Authors have no conflict of interest to declare.

Ethical Approval: All procedures performed in studies involving human participants were in
accordance with the ethical standards of the institutional and/or national research This is a
meta-analysis of retrospective studies which were conducted on already available data for

- 223 which formal consent was obtained. Therefore, institutional ethical approval was not required
- according on the law and the national ethical guidelines.
- 225 Patient Consent: Patient consent was not required due to the fact that this is a meta-analysis
- of retrospective studies for which formal consent was obtained. Furthermore, personal details
- of patients are not known/available/included in any part of the paper and/or any
- supplementary materials.
- 229
- 230

REFERENCES

- 232 1. Spiro RH, Huvos AG, Strong EW. Adenoid cystic carcinoma of salivary origin. A
- clinicopathologic study of 242 cases. Am J Surg 1974;128:512-520.
- 234 2. Spiro RH. Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg
 235 1997;174:495-498.
- 236 3. Luksic I, Suton P. Elective neck dissection in adenoid cystic carcinoma of head and neck:

237 yes or no? A systematic review. Eur Arch Otorhinolaryngol 2019;276:2957-2962.

4. Lee SY, Kim BH, Choi EC. Nineteen-year oncologic outcomes and the benefit of elective

neck dissection in salivary gland adenoid cystic carcinoma. Head Neck 2014;36:1796-1801.

5. Amit M, Na'ara S, Sharma K. Elective neck dissection in patients with head and neck

241 adenoid cystic carcinoma: an international collaborative study. Ann Surg Oncol

242 2015;22:1353-1359.

243 6. Cordesmeyer R, Kauffmann P, Laskawi R, Rau A, Bremmer F. The incidence of occult

244 metastasis and the status of elective neck dissection in salivary adenoid cystic carcinoma: a

single center study. Oral Surg Oral Med Oral Pathol Oral Radiol 2018;125:516-519.

246 7. Qian ZJ, Chen MM, Divi V, Megwalu UC. Impact of lymph node sampling on survival in

cN0 major salivary gland adenoid cystic carcinoma. Head Neck 2019;41:1903-1907.

8. Xiao R, Sethi RKV, Feng AL, Fontanarosa JB, Deschler DG. The role of elective neck

249 dissection in patients with adenoid cystic carcinoma of the head and neck. Laryngoscope


250 2019; 129:2094-2104.


- 9. Atallah S, Moya-Plana A, Malard O, Poissonnet G, Fakhry N, Bettoni J, et al. Should a
- neck dissection be performed on patients with cN0 adenoid cystic carcinoma? A REFCOR
- propensity score matching study. Eur J Cancer 2020 Jan 30. pii: S0959-8049(19)30894-9. doi:
- 254 10.1016/j.ejca.2019.12.026. [Epub ahead of print]

255	10. Ning C, Zhao T, Wang Z, Li D, Kou Y, Huang S. Cervical lymph node metastases in
256	salivary gland adenoid cystic carcinoma: a systematic review and meta-analysis. Cancer
257	Manag Res 2018;10:1677-1685.
258	11. Amit M, Binenbaum Y, Sharma K, Ramer N, Ramer I, Agbetoba A. Analysis of failure in
259	patients with adenoid cystic carcinoma of the head and neck. An international collaborative
260	study. Head Neck 2014;36:998-1004.
261	12. Ahmed I, Sutton AJ, Riley RD. Assessment of publication bias, selection bias, and
262	unavailable data in meta-analyses using individual participant data: a database survey. BMJ
263	2012;344:d7762.
264	
265	
266	
267	
268	

270 Figure legends


- Figure 1. Bias assessment plot for five-year OS
- Figure 2. Meta-analysis of five-year OS (all-stages patients)
- Figure 3. Meta-analysis of five-year OS (early-stage AdCCHN)
- Figure 4. Meta-analysis of five-year OS (advanced-stage AdCCHN)





Odds ratio meta-analysis plot [random effects]

Odds ratio meta-analysis plot [random effects]



Odds ratio meta-analysis plot [random effects]

Table 1. Occult neck metastases in patients with HNAdCC.

Author (year)	No. of patients	No. of END (%)	No of pts. with pN+ (%)	Oral cavity/Oropharynx N (%)	Sinonasal N (%)	MSG* N (%)
Amit (2015)	457	226 (49.5)	38 (17.3)	25 (21.5)	4 (16.7)	9 (10.6)
Cordesmeyer (2018)	59	34 (57.6)	7 (20.6)†			
Qian (2019)	1504 [‡]	1190 (79.1)				104 (8.7)
Xiao (2019)	2807 [§]	636 (22.7)	85 (13.4)			
Atallah (2020)	322	149 (46.3) [¶]	7 (4.7)	4 (57.1)	1 (14.3)	2 (28.6)

* major salivary glands

[†] 57.1% (4/7) of all occult neck metastases occured in oral cavity primaries

[‡] 314 patients had no lymph nodes sampled

§ 1422 patients (50.7%) had major salivary gland primaries

¹ after propensity score matching 96 patients were undergoing END submitted to survival analysis

 Table 2. Patient's demographic and clinical characteristics.

	No END	END
Age, mean (y)	63.2	61
Female (%)	61.9	58.4
MSG* (%)	52.5	81.8
T1/T2 stage (%)	65.4	64.5
Adjuvant radiotherapy (%)	68.6	74.3

* major salivary glands